drugset / Trial / NCT05236738

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

NCT05236738

Phase 1 Completed 42 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug absorption of atazanavir and cobicistat between the coadministration of the mini-tablet formulations in applesauce or chocolate pudding followed by water and the coadministration of atazanavir oral powder in applesauce and cobicistat oral tablet followed by water in healthy adult participants.

Timeline

Start
2022-05-13
Primary completion
2022-07-05
Completion
2022-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg Oral
Subject Atazanavir/Cobicistat Unknown 150 mg Oral
Subject Atazanavir/Cobicistat Unknown 300 mg Oral
Subject Cobicistat Small molecule 150 mg Oral

Indications

No indication recorded.